^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Non-nucleoside reverse transcriptase inhibitor

    Related drugs:
    19d
    ATLAS: Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults (clinicaltrials.gov)
    P3, N=618, Active, not recruiting, ViiV Healthcare | Trial completion date: Dec 2025 --> Dec 2029
    Trial completion date • Head-to-Head
    30d
    A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants (clinicaltrials.gov)
    P1, N=214, Recruiting, ViiV Healthcare | Trial completion date: Nov 2027 --> Jun 2027 | Trial primary completion date: Jul 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    2ms
    IM-CAPABLE: IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas (clinicaltrials.gov)
    P=N/A, N=55, Recruiting, University of Nebraska | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    2ms
    Retroelements in thyroid cancer: epigenetic plasticity, dedifferentiation, and therapeutic opportunities. (PubMed, Rev Endocr Metab Disord)
    Emerging data also indicate that reverse transcriptase inhibitors (e.g., lamivudine, nevirapine) can partially suppress retroelement activity, induce transcriptional reprogramming and restore radioiodine uptake in refractory thyroid tumors, highlighting a potential therapeutic vulnerability. By integrating cancer epigenetics and mobilome biology, this review reframes thyroid tumor evolution as a process shaped not only by genetic alterations but also by retroelement-mediated disruption of genome regulation. Retroelements may serve as biomarkers of aggressive transformation and as actionable targets in translational oncology.
    Review • Journal
    |
    BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • TERT (Telomerase Reverse Transcriptase)
    2ms
    Association of HPV on risk of HIV acquisition in african women: Analyses from MTN-020/ASPIRE. (PubMed, J Natl Cancer Inst)
    HPV clearance-related immune activation is strongly linked to HIV acquisition, likely due to increased CD4+ T cells and inflammation. These findings support HPV vaccination as a potential HIV prevention strategy and highlight the need to integrate HIV prevention into cervical cancer programs.
    Journal
    |
    CD4 (CD4 Molecule)
    2ms
    REPURPOSE: Phase II study of Efavirenz in platinum resistant or heavily pretreated high-grade serous ovarian cancer (ACTRN12625001259437)
    P2, N=48, Not yet recruiting, The University of Newcastle
    New P2 trial • Platinum resistant
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    efavirenz
    2ms
    CYP2B6 downregulation by cell-penetrating dominant-negative activating transcription factor 5 peptide in glioblastoma cells. (PubMed, Drug Metab Dispos)
    Among the cytochrome P450 enzyme superfamily, CYP2B6 metabolizes drugs such as cyclophosphamide, efavirenz, methadone, and ecstasy. SIGNIFICANCE STATEMENT: The study found that the transcription factor activating transcription factor 5 regulates CYP2B6 expression in glioblastoma cell lines. Introducing a transactivator of transcription-fused cell-penetrating dominant-negative activating transcription factor 5 peptide downregulates CYP2B6 protein expression, suggesting its potential for personalized dosing strategies by targeting CYP2B6.
    Journal
    |
    CYP2B6 (Cytochrome P450 Family 2 Subfamily B Member 6)
    |
    cyclophosphamide • efavirenz
    3ms
    Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs (clinicaltrials.gov)
    P2, N=50, Recruiting, Yale University | Trial completion date: Oct 2025 --> Mar 2027 | Trial primary completion date: Oct 2025 --> Mar 2027
    Trial completion date • Trial primary completion date
    3ms
    Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV (clinicaltrials.gov)
    P1, N=26, Active, not recruiting, University of Texas Southwestern Medical Center | Recruiting --> Active, not recruiting | Trial completion date: Sep 2025 --> Aug 2026 | Trial primary completion date: Sep 2025 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    4ms
    Efavirenz (EFV) Intensification (clinicaltrials.gov)
    P4, N=7, Completed, Washington University School of Medicine
    New P4 trial
    |
    efavirenz
    4ms
    DORAVIPEP: Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study (clinicaltrials.gov)
    P4, N=399, Completed, Hospital Clinic of Barcelona | Recruiting --> Completed
    Trial completion
    5ms
    The Quality of Life and Viral Control Effect of AIDS Patients After Long-acting Injection of Cabotegravir and Rilpivirine (clinicaltrials.gov)
    P=N/A, N=200, Not yet recruiting, National Taiwan University Clinical Trial Center
    New trial • HEOR